The European Investment Bank is lending €20 million to BioLamina, the Swedish biotech that supplies the laminin-based cell culture matrices used by stem cell therapy developers worldwide. The funding will support expanded production of laminin technologies and animal-free drug safety testing methods. BioLamina, the Stockholm-based biotechnology company that produces the protein scaffolding used to grow […]

This story continues at The Next Web